• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Ghanim, Y., Amin, N., Badrah, M., imbaby, S., Mostafa, S. (2023). COMPARING SERUM PENTRAXIN 3 IN DIABETIC PATIENTS WITH AND WITHOUT RETINOPATHY.. ALEXMED ePosters, 5(1), 23-24. doi: 10.21608/alexpo.2023.193808.1562
Yehia Mostafa Ghanim; Noha Amin; Mai Hesham Badrah; salma imbaby; Soad Zakaria Mohammed Mostafa. "COMPARING SERUM PENTRAXIN 3 IN DIABETIC PATIENTS WITH AND WITHOUT RETINOPATHY.". ALEXMED ePosters, 5, 1, 2023, 23-24. doi: 10.21608/alexpo.2023.193808.1562
Ghanim, Y., Amin, N., Badrah, M., imbaby, S., Mostafa, S. (2023). 'COMPARING SERUM PENTRAXIN 3 IN DIABETIC PATIENTS WITH AND WITHOUT RETINOPATHY.', ALEXMED ePosters, 5(1), pp. 23-24. doi: 10.21608/alexpo.2023.193808.1562
Ghanim, Y., Amin, N., Badrah, M., imbaby, S., Mostafa, S. COMPARING SERUM PENTRAXIN 3 IN DIABETIC PATIENTS WITH AND WITHOUT RETINOPATHY.. ALEXMED ePosters, 2023; 5(1): 23-24. doi: 10.21608/alexpo.2023.193808.1562

COMPARING SERUM PENTRAXIN 3 IN DIABETIC PATIENTS WITH AND WITHOUT RETINOPATHY.

Article 1, Volume 5, Issue 1, January 2023, Page 23-24  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2023.193808.1562
View on SCiNiTO View on SCiNiTO
Authors
Yehia Mostafa Ghanim1; Noha Amin2; Mai Hesham Badrah3; salma imbaby4; Soad Zakaria Mohammed Mostafa email 1
1Department of Internal Medicine (Diabetes, Metabolism and Lipidology Unit), Faculty of Medicine, Alexandria University.
2Department of Internal Medicine, Faculty of Medicine, Alexandria University
3Department of Internal Medicine Faculty of Medicine Alexandria University
4Department of clinical and chemical pathology Faculty of medicine, Alexandria university, Egypt.
Abstract
Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Diabetic retinopathy is one of the most prominent pathologic vascular complications of diabetes and is the most common cause of blindness in the working-age group.
The most common cause of vision loss in diabetic retinopathy is diabetic macular edema.Diabetic retinopathy can be classified into two categories: non-proliferative and proliferative. Risk factors include duration of diabetes, poor glycemic control, hypertension, diabetic nephropathy and dyslipidemia.
Screening is important to early detect preventable blindness. In type 2 diabetes patients, first eye examination should be initiated once a diagnosis of diabetes is confirmed, for type 1 diabetes, the timing being extended to 5 years after the onset of diabetes.
Pentraxins are a superfamily of evolutionarily conserved molecules with multi-functional roles in innate immunity and inflammation, such as regulation of complement activation and opsonization of pathogens. Pentraxin 3, a member of the pentraxin superfamily, includes C‐reactive protein and serum amyloid P. Pentraxin 3 is produced in response to inflammatory stimuli within a variety of cell types and tissues, in particular within the vasculature.
Pentraxin 3, as a long pentraxin, is produced by peripheral tissues and reflects impaired vascular endothelial function. Pentraxin 3 is an acute-phase reactant with a cyclic multimericstructure. Pentraxin 3 may reflect local inflammatory status in tissues and may serve as a biomarker of inflammation.
Keywords
PENTRAXIN 3; DIABETIC; RETINOPATHY
Supplementary Files
download 1562 Soad Zakaria Mohammed Mostafa.pdf
Statistics
Article View: 149
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.